Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

CXCL13 is a predictive biomarker in idiopathic multicentric Castleman disease

24 Nov 2022

Abstract excerpt

Idiopathic multicentric Castleman disease (iMCD) is a rare and poorly-understood cytokine storm-driven inflammatory disorder. Interleukin-6 (IL-6) is a known disease driver in some patients, but anti-IL-6 therapy with siltuximab is not effective in all patients, and biomarkers indicating success at an early time point following treatment initiation are lacking. Here we show, by comparison of levels of 1,178...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Histiocytic Disorders and Treatments
Share to Lymphoma Diagnosis and Treatment
Share to Viral-associated cancers and disorders

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 36433996
DOI: 10.1038/s41467-022-34873-7

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

CXCL13 is a predictive biomarker in idiopathic multicentric Castleman diseasePMID 36433996Read ↗

Castleman Disease: Updated Pathophysiology, Diagnostic Approach and Therapeutic StrategiesSemantic proximity Read ↗

Dysregulated lymphocyte localization in idiopathic multicentric Castleman diseaseSemantic proximity Read ↗

Cytokine Hub Classification of PASC, ME-CFS and other PASC-like ConditionsSemantic proximity Read ↗

Interleukin-6 Blockade With Tocilizumab In Idiopathic Multicentric Plasma Cell Variant Castleman Disease: Case reportSemantic proximity Read ↗

Increased IL6 plasma levels in indolent systemic mastocytosis patients are associated with high risk of disease progression.Semantic proximity Read ↗

CXCL13 as a Biomarker: Background and Utility in Multiple SclerosisSemantic proximity Read ↗

Idiopathic Multicentric Castleman Disease in Children: A Single-Center Retrospective AnalysisSemantic proximity Read ↗

Heterogeneous expression of cytokines accounts for clinical diversity and refines prognostication in CMML.Semantic proximity Read ↗

Targeting soluble immunoglobulins ameliorates idiopathic multicentric Castleman disease in a mouse modelSemantic proximity Read ↗

Idiopathic multicentric Castleman disease in a patient with an IgG4-related disease phenotype.Semantic proximity Read ↗

IL13Pred: A method for predicting immunoregulatory cytokine IL-13 inducing peptides for managing COVID-19 severitySemantic proximity Read ↗

Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: a comprehensive cytokine profiling study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.